Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma

Trial Profile

Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Oregovomab (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Quest PharmaTech
  • Most Recent Events

    • 07 Nov 2017 According to an OncoQuest media release, data will be presented at the International Meeting of European Society of Gynaecological Oncology (ESGO) 2017.
    • 26 Oct 2017 According to an OncoQuest media release, the final clinical study report is being compiled and expected to be presented to the regulatory authorities in the first half of 2018.
    • 18 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top